Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT03121846
Phase
PHASE2
Status
Unknown

Conditions

  • Soft Tissue Sarcoma, Adult, Stage II

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.

Study Details

This is a Prospective, Open-label, Single-Arm, Multi-center phase II clinical trial evaluating the efficacy and safety of Apatinib for Chemotherapy Failure Ⅳ Stage Soft Tissue Sarcoma.

Key Dates

Start date
May 1, 2017
Status verified
Mar 2017
Primary completion
Nov 1, 2018
Completion
May 1, 2019

Study Design

Enrollment
80 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib group
    apatinib 500mg po qd, 28 days for a cycle.

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: 2 year ]

Central Contacts